http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yasuhiro Kaneda (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Yasuhiro Kaneda 대한정신약물학회 2007 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.5 No.1
This mini-review focuses on the depression and suicide risk in patients with schizophrenia during the treatment by second generation antipsychotic drugs. Regarding depressive symptoms and depressive illness in schizophrenia, several studies have found a relationship between negative or positive symptoms and depressive symptoms. Also,“revealed depression”,“akinetic depression”, or“pharmacogenic depression” is reported to explain the presence of depression in schizophrenia. There are several good reasons to consider that second generation antipsychotic drugs may prove to have at least somewhat superior effects on depression in schizophrenia than first generation antipsychotic drugs: their relatively weak blockade at D2 receptors, minimal serum prolactin elevations, and minimal extrapyramidal symptoms. Regarding suicide in schizophrenia, depression is one of the important factors for suicide. Second generation antipsychotic drugs particularly clozapine are thought to be effective for suicide in schizophrenia, via several proposed mechanisms including an antidepressant effect. Over all, second generation antipsychotic drugs are considered to be effective for both depression and suicide in schizophrenia. However, since patients would have strong psychological reactions to their symptom improvement, which would make a maladaptive or adaptive response, it should be noted that changes in awareness associated with treatment be carefully monitored regardless of medications we choose. This mini-review focuses on the depression and suicide risk in patients with schizophrenia during the treatment by second generation antipsychotic drugs. Regarding depressive symptoms and depressive illness in schizophrenia, several studies have found a relationship between negative or positive symptoms and depressive symptoms. Also,“revealed depression”,“akinetic depression”, or“pharmacogenic depression” is reported to explain the presence of depression in schizophrenia. There are several good reasons to consider that second generation antipsychotic drugs may prove to have at least somewhat superior effects on depression in schizophrenia than first generation antipsychotic drugs: their relatively weak blockade at D2 receptors, minimal serum prolactin elevations, and minimal extrapyramidal symptoms. Regarding suicide in schizophrenia, depression is one of the important factors for suicide. Second generation antipsychotic drugs particularly clozapine are thought to be effective for suicide in schizophrenia, via several proposed mechanisms including an antidepressant effect. Over all, second generation antipsychotic drugs are considered to be effective for both depression and suicide in schizophrenia. However, since patients would have strong psychological reactions to their symptom improvement, which would make a maladaptive or adaptive response, it should be noted that changes in awareness associated with treatment be carefully monitored regardless of medications we choose.
-
-
THE NEXT-GENERATION INFRARED ASTRONOMY MISSION SPICA UNDER THE NEW FRAMEWORK
NAKAGAWA, TAKAO,SHIBAI, HIROSHI,ONAKA, TAKASHI,MATSUHARA, HIDEO,KANEDA, HIDEHIRO,KAWAKATSU, YASUHIRO The Korean Astronomical Society 2015 天文學論叢 Vol.30 No.2
We present the current status (as of August 2014) of SPICA (Space Infrared Telescope for Cosmology and Astrophysics), which is a mission optimized for mid- and far-infrared astronomy with a cryogenically cooled 3m-class telescope. SPICA is expected to achieve high spatial resolution and unprecedented sensitivity in the mid- and far-infrared, which will enable us to address a number of key problems in present-day astronomy, ranging from the star-formation history of the universe to the formation of planets. We have carried out the "Risk Mitigation Phase" activity, in which key technologies essential to the realization of the mission have been extensively developed. Consequently, technical risks for the success of the mission have been significantly mitigated. Along with these technical activities, the international collaboration framework of SPICA has been revisited, which resulted in la arger contribution from ESA than that in the original plan. To enable the ESA participation under the new framework, a SPICA proposal to ESA is under consideration as a medium-class mission under the framework of the ESA Cosmic Vision. The target launch year of SPICA under the new framework is the mid-2020s.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
